文献速递肿瘤 PET/CT核素与放射性配体治疗

新型CD147靶向纳米抗体用于肝癌免疫PET显像

A Novel CD147-Targeting Nanobody for Immuno-PET Imaging of Liver Cancer.
PubMed 文献 · J Nucl Med · 2026-07-01

研究构建了靶向CD147的纳米抗体DMN1,用18F标记后在同源CD147阳性与敲除肝癌细胞及皮下和原位小鼠肝癌模型中评估。结果显示[18F]FPy-DMN1标记率高、特异性强,注射后2小时肿瘤/血和肿瘤/肌肉比值高,3小时可清晰显示原位肝肿瘤,支持同日显像。

要点

  • CD147在约60% HCC中过表达而正常肝低表达,是肿瘤选择性显像的潜在靶点。
  • [18F]FPy-DMN1在CD147阳性肿瘤摄取3.82±0.93 %IA/g,显著高于阴性肿瘤0.21±0.02 %IA/g。
  • 注射后2小时肿瘤/血比值18.7±3.9、肿瘤/肌肉比值52.6±22.1,3小时可清晰显示原位肝肿瘤。

核心结论

  • [18F]FPy-DMN1是一种新型CD147特异性纳米抗体PET显像剂,具有高靶点特异性和适合同日显像的药代动力学,支持进一步开发用于肝癌显像和治疗反应监测。

研究设计与样本

  • 从免疫羊驼构建噬菌体展示库,经多轮免疫淘选获得CD147选择性纳米抗体,并用ELISA、生物膜干涉和流式细胞术在同源CD147阳性与敲除肝癌细胞系中表征。
  • 先导候选DMN1通过[18F]FPy吡啶基辅基偶联进行18F标记,在细胞实验及皮下和原位小鼠HCC模型中进行PET/CT显像与生物分布评估。

主要发现

  • DMN1对人CD147结合亲和力低(ELISA K D = 0.71 ± 0.1 nM),在CD147阳性与阴性异种移植瘤中确认特异性。
  • [18F]FPy-DMN1放射化学纯度>98%,摩尔活度3,700-11,100 GBq/μmol,小鼠血清3小时完整率87%。
  • 体内CD147阳性肿瘤摄取3.82 ± 0.93 %IA/g,阴性肿瘤0.21 ± 0.02 %IA/g;注射后2小时肿瘤/血比值18.7 ± 3.9、肿瘤/肌肉比值52.6 ± 22.1。
  • 原位肝肿瘤中[18F]FPy-DMN1在注射后3小时实现清晰肿瘤显像与显著对比,对照纳米抗体无肿瘤定位。

关键数值与推荐

  • HCC患者5年生存率约20%,约60%的HCC肿瘤过表达CD147而正常肝表达极低。
  • DMN1对人CD147的ELISA K D = 0.71 ± 0.1 nM。
  • [18F]FPy-DMN1放射化学纯度>98%,摩尔活度3,700-11,100 GBq/μmol,小鼠血清3小时完整率87%。
  • CD147阳性肿瘤摄取3.82 ± 0.93 %IA/g vs 阴性0.21 ± 0.02 %IA/g;2小时肿瘤/血18.7 ± 3.9、肿瘤/肌肉52.6 ± 22.1。

临床怎么用

  • 该显像剂支持同日PET显像流程,有望用于肝癌病灶显像及治疗反应监测,但当前仅为临床前数据,尚未进入患者应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, with a 5-y survival rate of approximately 20%. Many patients undergo locoregional therapy, and distinguishing viable tumor from treated necrotic tissue presents a significant clinical challenge with conventional imaging. CD147, a transmembrane glycoprotein overexpressed in approximately 60% of HCC tumors with minimal expression in normal liver, represents a promising target for tumor-selective molecular imaging to address this unmet clinical need. We aimed to develop and characterize a CD147-targeted nanobody-based PET imaging agent compatible with same-day clinical imaging workflows. Methods: We constructed a phage-display library from a llama immunized with recombinant human CD147. CD147-selective nanobodies were isolated through iterative immunopanning and characterized by enzyme-linked immunosorbent assay, biolayer interferometry, and flow cytometry using isogenic CD147-positive and CD147-knockout liver cancer cell lines. The lead candidate, denoted as DMN1, was radiolabeled with 18F via [18F]FPy pyridine-based prosthetic group conjugation. The radiolabeled nanobody was evaluated in cellular assays and further characterized in vivo using PET/CT imaging and biodistribution studies in subcutaneous and orthotopic murine HCC models. Results: DMN1 demonstrated low binding affinity to human CD147 (K D = 0.71 ± 0.1 nM, enzyme-linked immunosorbent assay), with specificity confirmed in CD147-positive versus CD147-negative xenografts. [18F]FPy-DMN1 was synthesized with high radiochemical purity (>98%), a molar activity of 3,700-11,100 GBq/μmol, and good serum stability (87% intact in mouse serum at 3 h). In vivo, [18F]FPy-DMN1 showed robust tumor accumulation in CD147-positive (3.82 ± 0.93 %IA/g) versus CD147-negative tumor xenografts (0.21 ± 0.02 %IA/g), with excellent tumor-to-background ratios at 2 h postinjection (tumor-to-blood ratio, 18.7 ± 3.9; tumor-to-muscle ratio, 52.6 ± 22.1). In orthotopic liver tumors, [18F]FPy-DMN1 enabled clear tumor visualization with striking contrast at 3 h postinjection, whereas the control nanobody showed no tumor localization. Conclusion: [18F]FPy-DMN1 is a novel CD147-specific nanobody-based PET imaging agent that demonstrates high target specificity and favorable pharmacokinetics for same-day imaging. Its rapid blood clearance, high tumor-to-background ratios, and successful visualization of orthotopic liver tumors support further development of this agent for imaging and monitoring treatment response in patients with liver cancer.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Nambiar DM, Esparza TJ, Lee W, et al. A Novel CD147-Targeting Nanobody for Immuno-PET Imaging of Liver Cancer. J Nucl Med. 2026. PMID: 41956563. doi:10.2967/jnumed.125.271565

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。